指南与共识心脑血管急症

国际儿茶酚胺敏感性多形性室性心动过速患者队列中药物与生活方式建议依从性的洞察

Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia.
指南 / 共识 · Europace · 2024-01-01
一句话结论CPVT患者中15%不依从药物、13.4%运动超推荐,女性、氟卡尼单药及对药物担忧与不依从独立相关(作者认为可通过针对性患者教育改善依从性)。

该研究为国际在线多语言调查,于2022年11月至2023年7月通过心脏病医生、同伴招募和社交媒体发放,纳入218例CPVT患者,其中200例(92%)被处方药物。采用经验证的运动依从性评定量表(MARS)和新开发的生活方式问卷评估自我报告的不依从,并用经验证问卷评估不依从原因。结果显示30例(15%)药物不依从、19例(13.4%)运动超过推荐、34例(17%)诊断后发生晕厥、心脏骤停复苏或适当的植入式心律转复除颤器放电。女性(OR 3.7,95%CI 1.3-12.0,P=0.019)、氟卡尼单药相比联合治疗(OR 6.8,95%CI 1.6-31.0,P=0.010)及对CPVT药物担忧陈述的更高认同度(OR 1.2,95%CI 1.1-1.3,P<0.001)与不依从独立相关。作者认为针对性的患者教育可能改善治疗依从性。

要点

  • 200例被处方药物的CPVT患者中30例(15%)对药物不依从,19例(13.4%)运动超过推荐。
  • 女性与药物不依从独立相关(OR 3.7,95%CI 1.3-12.0,P=0.019)。
  • 氟卡尼单药相比联合治疗与不依从独立相关(OR 6.8,95%CI 1.6-31.0,P=0.010)。
  • 对CPVT药物担忧陈述的认同度越高,不依从风险越高(OR 1.2,95%CI 1.1-1.3,P<0.001)。
  • 作者认为针对性的患者教育可能改善治疗依从性。

适用人群与场景

  • 国际CPVT患者队列,通过心脏病医生、同伴招募和社交媒体于2022年11月至2023年7月在线招募。
  • 218例完成调查,其中200例(92%)被处方药物;122例(61%)为女性,中位年龄33.5岁(四分位距22-50)。

处置流程与药物剂量

  • 103例(52%)被处方β受体阻滞剂联合氟卡尼,85例(43%)β受体阻滞剂单药,11例(6%)氟卡尼单药。

红旗征与不能漏的情况

  • 34例(17%)患者诊断后发生晕厥、心脏骤停复苏或适当的植入式心律转复除颤器放电。

研究设计与关键结果

  • 研究类型为国际在线多语言调查,218例CPVT患者完成调查,其中200例(92%)被处方药物;122例(61%)女性,中位年龄33.5岁(四分位距22-50)。
  • 药物处方:103例(52%)β受体阻滞剂联合氟卡尼,85例(43%)β受体阻滞剂,11例(6%)氟卡尼。
  • 34例(17%)诊断后发生晕厥、心脏骤停复苏或适当的植入式心律转复除颤器放电;19例(13.4%)运动超过推荐;30例(15%)药物不依从。
  • 女性(OR 3.7,95%CI 1.3-12.0,P=0.019)、氟卡尼单药相比联合治疗(OR 6.8,95%CI 1.6-31.0,P=0.010)及对CPVT药物担忧陈述的更高认同度(OR 1.2,95%CI 1.1-1.3,P<0.001)与不依从独立相关。

证据类型、等级与局限

  • 证据类型:国际在线调查(横断面研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为针对性的患者教育可能改善治疗依从性,尤其应关注女性、氟卡尼单药治疗者及对CPVT药物有担忧的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIMS: In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare inherited arrhythmia syndrome, arrhythmic events can be prevented by medication and lifestyle recommendations. In patients who experience breakthrough arrhythmic events, non-adherence plays an essential role. We aimed to investigate the incidence and potential reasons for non-adherence to medication and lifestyle recommendations in a large, international cohort of patients with CPVT.

METHODS AND RESULTS: An online multilingual survey was shared with CPVT patients worldwide by their cardiologists, through peer-recruitment, and on social media from November 2022 until July 2023. Self-reported non-adherence was measured using the validated Medication Adherence Rating Scale (MARS) and a newly developed questionnaire about lifestyle. Additionally, validated questionnaires were used to assess potential reasons for medication non-adherence. Two-hundred-and-eighteen patients completed the survey, of whom 200 (92%) were prescribed medication [122 (61%) female; median age 33.5 years (interquartile range: 22-50)]. One-hundred-and-three (52%) were prescribed beta-blocker and flecainide, 85 (43%) beta-blocker, and 11 (6%) flecainide. Thirty-four (17%) patients experienced a syncope, aborted cardiac arrest or appropriate implantable cardioverter defibrillator shock after diagnosis. Nineteen (13.4%) patients were exercising more than recommended. Thirty (15%) patients were non-adherent to medication. Female sex [odds ratio (OR) 3.7, 95% confidence interval (CI) 1.3-12.0, P = 0.019], flecainide monotherapy compared to combination therapy (OR 6.8, 95% CI 1.6-31.0, P = 0.010), and a higher agreement with statements regarding concerns about CPVT medication (OR 1.2, 95% CI 1.1-1.3, P < 0.001) were independently associated with non-adherence.

CONCLUSION: The significant rate of non-adherence associated with concerns regarding CPVT-related medication, emphasizes the potential for improving therapy adherence by targeted patient education.

来源:Europace,查看原文。版权归原作者所有。

参考来源

  1. Peltenburg PJ, van den Heuvel LM, Kallas D, et al. Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia. Europace. 2024. PMID: 38349347. doi:10.1093/europace/euae044

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。